MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
Organization & Developments: Amneal
Parents
Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
Children
*Amneal is a generic and specialty pharmaceutical company
2019: Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.
2019: Amneal Pharmaceuticals: Insiders Continue To Buy As The Stock Price Slides_seekingalpha.com
2021: Our First Assessment Of Amneal Pharmaceuticals Stock
2022: Amneal Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Amneal Pharmaceuticals: A Small 'Thumbs Up'_ seekingalpha.com
2023: Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company_ seekingalpha.com
2024: Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2025: Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment
2025: Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
2025: Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth
2025: Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Jumps
*Key People: Amneal
Finance & Acquisitions: Amneal